Alev Türker

ORCID: 0000-0001-5265-8128
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Cancer Treatment and Pharmacology
  • Lung Cancer Treatments and Mutations
  • Multiple Myeloma Research and Treatments
  • Acute Myeloid Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Vascular Tumors and Angiosarcomas
  • Renal cell carcinoma treatment
  • Cardiac tumors and thrombi
  • Gastrointestinal Tumor Research and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Brain Metastases and Treatment
  • Colorectal Cancer Treatments and Studies
  • Glioma Diagnosis and Treatment
  • Medical Imaging and Pathology Studies
  • Acute Lymphoblastic Leukemia research
  • Multiple and Secondary Primary Cancers
  • Cancer therapeutics and mechanisms
  • Chronic Lymphocytic Leukemia Research
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Economic and Financial Impacts of Cancer
  • Endometrial and Cervical Cancer Treatments

Hacettepe University
2009-2024

Hacettepe University Hospital
2003-2023

Bernstein Center for Computational Neuroscience Tübingen
2003

The Royal Free Hospital
1996

University College London
1996

Ankara University
1993

Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients extensive-stage small lung cancer (SCLC). It remained unknown whether adding a programmed (PD-1) inhibitor provided similar or better benefits SCLC, which would add evidence on efficacy of checkpoint SCLC. Objective To evaluate and adverse event profile PD-1 serplulimab plus compared placebo as Design, Setting, Participants This international,...

10.1001/jama.2022.16464 article EN JAMA 2022-09-27

COVID-19 pandemic could create a collateral damage to cancer care denoting disruptions in due significant burden on healthcare and resource allocations. Herein, we evaluate the early changes inpatient outpatient oncology clinics take snapshot of this at Hacettepe University Cancer Institute.

10.1136/bmjspcare-2020-002468 article EN other-oa BMJ Supportive & Palliative Care 2020-07-14

Though not very common, solid tumor involvement of the bone marrow (BM) may have serious consequences. Recent studies shown that mean platelet volume (MPV) is a good indicator for BM disease in differential diagnosis thrombocytopenia. We investigated significance MPV metastasis patients with tumors. Patients histologically-verified tumors whom biopsy specimens were available (n = 121) and healthy controls 62) included this retrospective study. A total 183 individuals analyzed. Of patients,...

10.1111/j.1751-553x.2007.00947.x article EN International Journal of Laboratory Hematology 2007-08-07

Rituximab is an anti-CD20 chimeric murine/human mAb mainly used to treat certain types of lymphoproliferative malignancies and autoimmune diseases. Although it has been in the treatment vasculitis recent years, rarely triggers severe vascular skin reactions such as leukocytoclastic (LCV). Physicians should be aware this rare adverse event that requires discontinuation rituximab, which can occur days or even weeks after rituximab treatment. Here, we report a case LCV observed patient with...

10.1097/cad.0000000000001638 article EN Anti-Cancer Drugs 2024-07-23

Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of will experience relapse following ASCT. High-dose sequential (HDSC) can intensify conventional salvage treatment and improve outcome ASCT maximal debulking tumor load use non-cross resistant drugs, each at their tolerated doses. We conducted a phase II study in 40...

10.1080/10428190600570958 article EN Leukemia & lymphoma/Leukemia and lymphoma 2006-01-01

To achieve long-term disease-free survival, high-dose therapy and autologous stem cell transplantation (ASCT) is the current standard approach in patients with relapsed or refractory Hodgkin disease (HD) non-Hodgkin lymphoma (NHL). Because chemosensitivity a significant factor determining eligibility, it critical to select salvage chemotherapy regimen that has potential induce high response rate low nonhematologic toxicity. In this phase II study, 49 HD (n = 22) NHL 27) median age of 42...

10.1016/j.bbmt.2005.05.014 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2005-08-26

Several studies have suggested that sarcopenia is associated with an increased treatment toxicity in patients cancer. The aim of this study to evaluate the relationship between and anthracycline-related cardiotoxicity.Patients who received anthracycline-based chemotherapy 2014 2018 had baseline abdominal CT follow-up echocardiography after anthracycline were included. European Society Cardiology ejection fraction criteria American Echocardiography diastolic dysfunction used for definition...

10.1136/bmjspcare-2021-003197 article EN BMJ Supportive & Palliative Care 2021-09-03

<i>Background:</i> We have evaluated the clinical efficacy and toxicity of a modified etoposide, methylprednisolone, cytarabine cisplatin (ESHAP) chemotherapy regimen that has been used by Hacettepe University Department Medical Oncology (Ankara, Turkey) since 1993. <i>Methods:</i> Thirty-two patients (18 men 14 women) with refractory or recurrent non-Hodgkin’s lymphoma (NHL) were treated this protocol. The median age was 39 years (range 21–66 years). Patients...

10.1159/000066768 article EN Chemotherapy 2002-01-01

Posterior leukoencephalopathy syndrome is a recently described involving mainly parieto-occipital gray/white matter of the brain. It occurs secondary to various clinical entities, like hypertension and immunosuppressive therapy. Few cases after combination chemotherapy have been reported. This study describes 36-year-old woman with primary refractory T-cell lymphoma, who developed central nervous system toxicity due treatment intrathecal methotrexate intravenous ifosfamide, idarubicine...

10.1080/10428190500234424 article EN Leukemia & lymphoma/Leukemia and lymphoma 2005-11-02

Synovial sarcoma (SS) is a malignant mesenchymal tumor, which comprises 5%-10% of all the sarcomas. There insufficient information on prognostic factors and salvage treatments advanced SS. In this study, we aimed to further clarify clinicopathological features, factors, treatment modalities in SS.A total 45 SS patients followed up between 2001 2015 at our cancer institute, Department Medical Oncology, were retrospectively evaluated. Eleven initially metastatic, remaining developed metastasis...

10.4103/ijc.ijc_169_17 article EN Indian Journal of Cancer 2017-01-01

Primary cutaneous infection by <i>Aspergillus</i> spp. is an uncommon form of aspergillosis in patients with severe immunosuppression, e.g. HIV or hematological malignancies. Disruption the dermal integrity trauma maceration, followed colonization wound creates a suitable environment for infection. Despite aggressive therapy amphotericin, primary can lead to disseminated disease fatal consequences. Tuberculosis another rare malignancies, but when present it usually disseminated....

10.1159/000072452 article EN Chemotherapy 2003-01-01

Objective In patients with non-Hodgkin lymphoma (NHL), we investigated 18 F FDG PET/computed tomography (CT) parameters, clinical findings, laboratory and bone marrow involvement (BMI) status for predictive methods in progression-free survival (PFS) overall (OS), whether PET/CT could take the place of biopsy (BMB). Methods The performance (BM PET ) was evaluated. prognostic value maximum standardized uptake (SUVmax), metabolic tumor volume (MTV), stage, international index (IPI) score, IPI...

10.1097/mnm.0000000000001182 article EN Nuclear Medicine Communications 2020-03-25
Coming Soon ...